Soleus Capital remains a significant passive holder at 8.1%. Monitor for any future conversion to a 13D filing, which would signal activist intent, especially given the recent positive Q3 earnings and raised guidance.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $11.81entry
- T+1 · 6d ago +1.52%α +0.21% · $11.99
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Soleus Capital Master Fund filed an amended Schedule 13G disclosing a 8.1% passive stake in NovoCure as of September 30, 2026, representing 9,425,776 ordinary shares. The filing is an amendment to a prior 13G/A from May 2026, but the current document does not provide the prior stake figures for comparison, so the direction of change cannot be determined from the filing alone.
Key Financial Metrics
Key Facts
- Soleus Capital Master Fund, L.P. reported beneficial ownership of 9,425,776 ordinary shares of NovoCure Ltd.
- The stake represents 8.1% of the 116,915,959 ordinary shares outstanding as of October 23, 2026.
- The filing is an amendment to a Schedule 13G filed under Rule 13d-1(c), indicating passive investment intent.
- The reporting persons include Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, each disclaiming beneficial ownership except as required under Section 13(d).
Financial Impact
9,425,776 shares valued at approximately $129M based on $1.6B market cap and 116.9M shares outstanding.
Risk Factors
- The filing does not provide prior stake figures, so the direction of change (increase, decrease, or unchanged) is unknown.
- A passive 13G filing can be amended to a 13D if the investor's intent changes, potentially leading to activist pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001213900-26-117546 |
| Document: 0001213900-26-117546-index.html | 0001213900-26-117546 |
| Document: 0001213900-26-117546.txt | 0001213900-26-117546 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Viewing Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers